 BOSTON, Aug. 18, 2020 GLOBE NEWSWIRE -- Block Leviton LLP a national securities litigation firm, is investigating whether Applied Therapeutics, Inc. NASDAQ: APLT and certain of its executives may be liable for securities fraud. If you purchased or acquired shares of Applied Therapeutics and have questions about your legal rights or possess information relevant to this matter, please contact Block Leviton attorneys at 617 398-5600, via email at or at On August 17, 2020, Applied Therapeutics disclosed that the U.S. Food and Drug Administration had placed a partial clinical hold on the Companys ACTION-Kids study, evaluating the Companys AT-007 product for the treatment of galactosemia. The FDA cited the need for additional technical information relating to ensuring that each study participant has access to the drugs benefits. On this news, shares of Applied Therapeutics stock fell 3.53 per share, or 12.07, to close at 25.71.If you purchased or acquired shares of Applied Therapeutics and have questions about your legal rights or possess information relevant to this matter, please contact Block Leviton attorneys at 617 398-5600, via email at or at Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the countrys financial markets. The firm represents many of the nations largest institutional investors as well as individual investors in securities litigation throughout the United States. The firms lawyers have recovered billions of dollars for its clients.This notice may constitute attorney advertising.CONTACT: BLOCK LEVITON LLP 260 Franklin St., Suite 1860 Boston, MA 02110 Phone: 617 398-5600 Email: SOURCE: Block Leviton LLP 